ScreenerHero

SGMT Sagimet Biosciences Inc.

NAS · US · Healthcare · Biotechnology · sagimet.com
8.880USD+1.37%Mkt Cap: 629.67M $P/E: —

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap629.67M USD
Enterprise Value306.32M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-51.04M USD
Revenue/Share—
Last Price8.880 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.74
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.11
EPS (TTM)-1.23
EPS (Forward)-1.30
52W Range
4.50063% of range11.45
52W High11.45 USD
52W Low4.500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.82%
ROA-43.82%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.65M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-4.42%
Net Debt-238.19M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio45.02
Quick Ratio44.31
Book Value/Sh4.15 USD
Cash/Share3.86 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.91 USD
Upside (mean)+214.3%
Target Range7.000 USD – 56.00 USD
7.000+214.3% to mean56.00
# Analysts11
Ownership
Shares Out.70.34M
Float56.57M
Insiders2.95%
Institutions73.20%
Short Interest
Short Ratio9.9d
Short % Float16.81%
Short % Out.16.51%
Shares Short10.26M
Short (prev mo.)11.75M
Technical
SMA 509.786 (-9.3%)
SMA 2007.188 (+23.5%)
Beta3.49
S&P 52W Chg16.45%
Avg Vol (30d)1.43M
Avg Vol (10d)1.99M
Technical Indicators
RSI (14)41.3
MACD-0.2157
MACD Signal0.0176
MACD Hist.-0.2333
BB Upper11.78 USD
BB Middle10.05 USD
BB Lower8.324 USD
BB Width34.41%
ATR (14)0.6995 USD
Vol Ratio (20d)0.42x